Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control
| Autor: | Luc Vakaet, Antony Verbaeys, Valérie Fonteyne, Wilfried J. De Neve, Gert De Meerleer, Ludwig Denoyette, Geert Villeirs, Nicolas Lummen |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.drug_class medicine.medical_treatment Planning target volume Urology Rectum Prostate cancer Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Survivors Survival analysis Aged business.industry Prostatic Neoplasms Androgen Antagonists Hematology Middle Aged Prostate-Specific Antigen Intensity-modulated radiation therapy medicine.disease Androgen Combined Modality Therapy Survival Analysis Radiation therapy Treatment Outcome medicine.anatomical_structure Cohort Radiotherapy Intensity-Modulated Morbidity Neoplasm Recurrence Local business |
| Zdroj: | Radiotherapy and Oncology. 82:160-166 |
| ISSN: | 0167-8140 |
| DOI: | 10.1016/j.radonc.2006.12.007 |
| Popis: | Purpose To report on late morbidity and biochemical relapse-free survival (bRFS) after intensity-modulated radiation therapy (IMRT) for prostate cancer. Methods Between 1998 and 2005 133 patients were treated with IMRT for T(1-4) N0 M0 prostate cancer. The median follow-up time was 36 months. In a first cohort, patients received a median planning target volume (PTV) dose of 74 Gy with a hard constraint on maximum rectum dose of 72 Gy (74R72, n = 51). Later, median PTV and maximum rectum dose were increased to 76 and 74 Gy, respectively (76R74; n = 82). We defined low-risk ( n = 20), intermediate-risk ( n = 70) and high-risk ( n = 43) groups. Androgen deprivation was given to patients in the intermediate- and high-risk group. Late gastro-intestinal (GI) and genito-urinary (GU) morbidity and biochemical relapse, in accordance with the ASTRO consensus, were recorded. Results We observed grade 2 GI (17%) and GU (19%), grade 3 GI (1%) and GU (3%) late toxicities. Except for hematuria, the median duration of side-effects was 6 months. Biochemical relapse-free survival (bRFS) at 3 and 5 years was 88% and 83%, respectively, with a significantly better 3-year bRSF for the 76R74 than for the 74R72 group ( p = 0.01). Five-year bRFS for patients in the low-risk, intermediate-risk and high-risk group was 100%, 94% and 74%, respectively ( p Conclusion IMRT for localized or locally advanced prostate cancer combines low morbidity with excellent biochemical control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect